| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1086115246 |
| P356 | DOI | 10.1186/S12964-017-0177-Y |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1186/s12964-017-0177-y |
| P8608 | Fatcat ID | release_s6kdg6y2szc43omgizee4sjjtq |
| P932 | PMC publication ID | 5480189 |
| P698 | PubMed publication ID | 28637459 |
| P50 | author | Majid Khoshmirsafa | Q61777094 |
| Hossein Aazami | Q57569115 | ||
| Farhad Seif | Q61777092 | ||
| P2093 | author name string | Monireh Mohsenzadegan | |
| Mohammadali Bahar | |||
| Gholamreza Sedighi | |||
| P2860 | cites work | Evolution of JAK-STAT pathway components: mechanisms and role in immune system development | Q21134741 |
| A transcriptional corepressor of Stat1 with an essential LXXLL signature motif | Q24290918 | ||
| TYK2 and JAK2 are substrates of protein-tyrosine phosphatase 1B | Q24291860 | ||
| The T cell protein tyrosine phosphatase is a negative regulator of janus family kinases 1 and 3 | Q24292506 | ||
| PTP1B regulates leptin signal transduction in vivo | Q24294879 | ||
| Inhibition of Stat1-mediated gene activation by PIAS1 | Q24310082 | ||
| A family of cytokine-inducible inhibitors of signalling | Q24313168 | ||
| A new protein containing an SH2 domain that inhibits JAK kinases | Q24313242 | ||
| Suppressors of cytokine signaling 4 and 5 regulate epidermal growth factor receptor signaling | Q24321251 | ||
| Janus kinases in immune cell signaling | Q24322021 | ||
| Negative Regulation of Interleukin-12 Signaling by Suppressor of Cytokine Signaling-1 | Q62819402 | ||
| Loss of suppressor of cytokine signaling 1 in helper T cells leads to defective Th17 differentiation by enhancing antagonistic effects of IFN-gamma on STAT3 and Smads | Q80825258 | ||
| Reciprocal roles of STAT3 and STAT5 in nasal polyposis | Q84948852 | ||
| SOCS-3 regulates onset and maintenance of T(H)2-mediated allergic responses | Q47777274 | ||
| Protein Inhibitor of Activated STAT3 Regulates Migration, Invasion, and Activation of Fibroblast-like Synoviocytes in Rheumatoid Arthritis. | Q48088661 | ||
| Molecular modeling study of CP-690550 derivatives as JAK3 kinase inhibitors through combined 3D-QSAR, molecular docking, and dynamics simulation techniques. | Q51035836 | ||
| Role of T-bet in commitment of TH1 cells before IL-12-dependent selection. | Q51065721 | ||
| A betulinic acid derivative SH479 inhibits collagen-induced arthritis by modulating T cell differentiation and cytokine balance. | Q51080407 | ||
| IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells. | Q51998742 | ||
| Ruxolitinib - better prognostic impact in low-intermediate 1 risk score: evaluation of the 'rete ematologica pugliese' (REP) in primary and secondary myelofibrosis. | Q53064328 | ||
| SUMO conjugation of STAT1 protects cells from hyperresponsiveness to IFNγ. | Q54367716 | ||
| General nature of the STAT3-activated anti-inflammatory response. | Q54570920 | ||
| Deficient SOCS3 expression in CD4+CD25+FoxP3+ regulatory T cells and SOCS3-mediated suppression of Treg function | Q56901192 | ||
| Interferon-induced nuclear factors that bind a shared promoter element correlate with positive and negative transcriptional control | Q57055074 | ||
| Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases | Q38177875 | ||
| A STAT protein domain that determines DNA sequence recognition suggests a novel DNA-binding domain | Q38296506 | ||
| SAF-Box, a conserved protein domain that specifically recognizes scaffold attachment region DNA. | Q38308113 | ||
| The JAK-STAT pathway: impact on human disease and therapeutic intervention | Q38317993 | ||
| Cooperative DNA binding and sequence-selective recognition conferred by the STAT amino-terminal domain | Q38354217 | ||
| Regulation of antiviral T cell responses by type I interferons | Q38384145 | ||
| Tyrosine kinase 2 - Surveillant of tumours and bona fide oncogene. | Q38657462 | ||
| Antagonizing STAT3 activation with benzo[b]thiophene 1, 1-dioxide based small molecules | Q38741954 | ||
| Adipocyte STAT5 deficiency promotes adiposity and impairs lipid mobilisation in mice | Q38794158 | ||
| The increasing complexity of the ubiquitin code | Q38845500 | ||
| A novel JAK inhibitor, peficitinib, demonstrates potent efficacy in a rat adjuvant-induced arthritis model | Q39002481 | ||
| Forkhead box protein 3 in human nasal polyp regulatory T cells is regulated by the protein suppressor of cytokine signaling 3. | Q39116327 | ||
| The emerging safety profile of JAK inhibitors in rheumatic disease | Q39157033 | ||
| ISG12a inhibits HCV replication and potentiates the anti-HCV activity of IFN-α through activation of the Jak/STAT signaling pathway independent of autophagy and apoptosis | Q39253364 | ||
| STA-21, a STAT-3 inhibitor, attenuates the development and progression of inflammation in collagen antibody-induced arthritis. | Q39311176 | ||
| PIAS proteins modulate transcription factors by functioning as SUMO-1 ligases. | Q39695522 | ||
| Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. | Q39719120 | ||
| Enhancement of antiproliferative activity of gamma interferon by the specific inhibition of tyrosine dephosphorylation of Stat1. | Q40019782 | ||
| Stat1 serine phosphorylation occurs independently of tyrosine phosphorylation and requires an activated Jak2 kinase | Q40023873 | ||
| Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management | Q40418584 | ||
| SUMO modification of STAT1 and its role in PIAS-mediated inhibition of gene activation | Q40645462 | ||
| Structure and function of SH2-domain containing tyrosine phosphatases. | Q40813395 | ||
| The SOCS box of SOCS-1 accelerates ubiquitin-dependent proteolysis of TEL-JAK2. | Q40816941 | ||
| Characterization of specific DNA-binding factors activated by double-stranded RNA as positive regulators of interferon alpha/beta-stimulated genes | Q41283879 | ||
| Src mediates cytokine-stimulated gene expression in airway myocytes through ERK MAPK. | Q41895953 | ||
| Phosphotyrosine signaling: evolving a new cellular communication system | Q42413402 | ||
| IFN-alpha is not sufficient to drive Th1 development due to lack of stable T-bet expression | Q42497613 | ||
| Loss of SOCS3 in T helper cells resulted in reduced immune responses and hyperproduction of interleukin 10 and transforming growth factor-beta 1 | Q42766950 | ||
| Is selection for TCR affinity a factor in cytokine polarization? | Q43697227 | ||
| The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop | Q24533774 | ||
| Regulation of Jak2 through the ubiquitin-proteasome pathway involves phosphorylation of Jak2 on Y1007 and interaction with SOCS-1. | Q24537294 | ||
| Physical and functional interactions of histone deacetylase 3 with TFII-I family proteins and PIASxbeta | Q24538513 | ||
| Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein | Q24641913 | ||
| The STATs in cell stress-type responses | Q24799716 | ||
| Ubiquitin modifications | Q26751380 | ||
| Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases | Q26775111 | ||
| Linear ubiquitination signals in adaptive immune responses | Q27027872 | ||
| Structure of the ERM protein moesin reveals the FERM domain fold masked by an extended actin binding tail domain | Q27622801 | ||
| Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family | Q27666375 | ||
| Mechanisms underlying ubiquitination | Q27860656 | ||
| How cells respond to interferons | Q27861006 | ||
| High-throughput immunoblotting. Ubiquitiin-like protein ISG15 modifies key regulators of signal transduction | Q27863761 | ||
| Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions | Q28118180 | ||
| Signaling through scaffold, anchoring, and adaptor proteins | Q28131792 | ||
| CIS3/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2 | Q28140132 | ||
| Involvement of PIAS1 in the sumoylation of tumor suppressor p53 | Q28189956 | ||
| PIASx is a transcriptional co-repressor of signal transducer and activator of transcription 4 | Q28201360 | ||
| Signaling through the JAK/STAT pathway, recent advances and future challenges | Q28201804 | ||
| The SOCS box: a tale of destruction and degradation | Q28205975 | ||
| Impaired IFN-gamma-dependent inflammatory responses in human keratinocytes overexpressing the suppressor of cytokine signaling 1 | Q28206163 | ||
| Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals | Q28236222 | ||
| Cloning and characterization of Gu/RH-II binding protein | Q28240024 | ||
| Modification of proteins by ubiquitin and ubiquitin-like proteins | Q28244250 | ||
| The human and mouse complement of SH2 domain proteins-establishing the boundaries of phosphotyrosine signaling | Q28247905 | ||
| Specific inhibition of Stat3 signal transduction by PIAS3 | Q28255665 | ||
| Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance | Q28269352 | ||
| Structure, function, and regulation of STAT proteins | Q28282800 | ||
| A single phosphotyrosine residue of Stat91 required for gene activation by interferon-gamma | Q28298440 | ||
| Dihydroartemisinin as a Putative STAT3 Inhibitor, Suppresses the Growth of Head and Neck Squamous Cell Carcinoma by Targeting Jak2/STAT3 Signaling | Q28552654 | ||
| Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibition of LIF and IL-6 signal transduction | Q28588105 | ||
| Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak/STAT pathway | Q28609398 | ||
| ISG15: a ubiquitin-like enigma | Q28612249 | ||
| BJ-3105, a 6-Alkoxypyridin-3-ol Analog, Impairs T Cell Differentiation and Prevents Experimental Autoimmune Encephalomyelitis Disease Progression | Q36251241 | ||
| JAK and STAT signaling molecules in immunoregulation and immune-mediated disease | Q36404704 | ||
| Signal transduction pathways and transcriptional regulation in the control of Th17 differentiation | Q36571580 | ||
| The JAK-STAT signaling pathway: input and output integration | Q36740971 | ||
| In vivo studies fail to reveal a role for IL-4 or STAT6 signaling in Th2 lymphocyte differentiation | Q36858595 | ||
| Cytokine signaling modules in inflammatory responses | Q37133450 | ||
| Priming for T helper type 2 differentiation by interleukin 2-mediated induction of interleukin 4 receptor alpha-chain expression | Q37387939 | ||
| Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction. | Q37541469 | ||
| FERM proteins in animal morphogenesis | Q37549588 | ||
| What determines Th2 differentiation, in vitro and in vivo? | Q37692831 | ||
| Phosphorylation meets nuclear import: a review | Q37823682 | ||
| Interferon-stimulated gene 15 and the protein ISGylation system | Q37824472 | ||
| Suppressors of cytokine signaling (SOCS) proteins and JAK/STAT pathways: regulation of T-cell inflammation by SOCS1 and SOCS3. | Q37867360 | ||
| The JAK-STAT pathway at twenty | Q38004201 | ||
| The Lnk adaptor protein: a key regulator of normal and pathological hematopoiesis | Q38044625 | ||
| Stats: transcriptional control and biological impact | Q29547776 | ||
| STATs and gene regulation | Q29547796 | ||
| Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation | Q29614840 | ||
| SUMO--nonclassical ubiquitin | Q29620234 | ||
| Momelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia | Q30244032 | ||
| Type I interferons directly inhibit regulatory T cells to allow optimal antiviral T cell responses during acute LCMV infection | Q33569835 | ||
| A Cell-permeable Stat3 SH2 Domain Mimetic Inhibits Stat3 Activation and Induces Antitumor Cell Effects in Vitro | Q33679564 | ||
| Negative regulators of cytokine signal transduction | Q33754091 | ||
| The signaling suppressor CIS controls proallergic T cell development and allergic airway inflammation. | Q33855162 | ||
| The role of STAT proteins in growth hormone signaling | Q33941394 | ||
| Serine phosphorylation of STATs | Q33941422 | ||
| Modulation of STAT signaling by STAT-interacting proteins | Q33941428 | ||
| Structural and evolutionary relationships among protein tyrosine phosphatase domains | Q34012560 | ||
| STAT proteins and transcriptional responses to extracellular signals | Q34069764 | ||
| SH2-B family members differentially regulate JAK family tyrosine kinases | Q34105915 | ||
| Cytokine signaling in 2002: new surprises in the Jak/Stat pathway | Q34126053 | ||
| Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). | Q34169114 | ||
| CD45: new jobs for an old acquaintance | Q34232649 | ||
| The JAK/STAT signaling pathway | Q34305849 | ||
| JAKs and STATs in immunity, immunodeficiency, and cancer | Q34321767 | ||
| Interferon induces a 15-kilodalton protein exhibiting marked homology to ubiquitin | Q34396930 | ||
| A new RING for SUMO: wrestling transcriptional responses into nuclear bodies with PIAS family E3 SUMO ligases | Q34455419 | ||
| Suppressors of cytokine signalling (SOCS) in the immune system | Q34716329 | ||
| Canonical and non-canonical JAK-STAT signaling | Q34855617 | ||
| A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel®) in client-owned dogs with atopic dermatitis | Q34866838 | ||
| Plasticity of CD4+ T cell lineage differentiation. | Q34982725 | ||
| A blinded, randomized clinical trial comparing the efficacy and safety of oclacitinib and ciclosporin for the control of atopic dermatitis in client-owned dogs | Q35194645 | ||
| The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families | Q35211894 | ||
| Class II cytokine receptors and their ligands: key antiviral and inflammatory modulators | Q35219039 | ||
| Regulation of JAK-STAT signalling in the immune system | Q35605437 | ||
| SUMO-specific protease 1 is critical for early lymphoid development through regulation of STAT5 activation | Q35714635 | ||
| Repression of Smad transcriptional activity by PIASy, an inhibitor of activated STAT. | Q35813575 | ||
| Suppression of cytokine signaling by SOCS3: characterization of the mode of inhibition and the basis of its specificity | Q35822851 | ||
| Potent and selective phosphopeptide mimetic prodrugs targeted to the Src homology 2 (SH2) domain of signal transducer and activator of transcription 3. | Q35869426 | ||
| A SHPing tale: perspectives on the regulation of SHP-1 and SHP-2 tyrosine phosphatases by the C-terminal tail | Q36220787 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P921 | main subject | cell | Q7868 |
| enzyme | Q8047 | ||
| peptide | Q172847 | ||
| transcription factor | Q407384 | ||
| transport protein | Q2111029 | ||
| lymphocyte subsets | Q66004891 | ||
| hemic and immune systems | Q70202933 | ||
| P304 | page(s) | 23 | |
| P577 | publication date | 2017-06-21 | |
| P1433 | published in | Cell Communication and Signaling | Q1254390 |
| P1476 | title | The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells | |
| P478 | volume | 15 |
| Q99628784 | A Perspective on Erythropoietin as a Potential Adjuvant Therapy for Acute Lung Injury/Acute Respiratory Distress Syndrome in Patients with COVID-19 |
| Q90384581 | Anti-Inflammatory Mechanisms of Koreanaside A, a Lignan Isolated from the Flower of Forsythia koreana, against LPS-Induced Macrophage Activation and DSS-Induced Colitis Mice: The Crucial Role of AP-1, NF-κB, and JAK/STAT Signaling |
| Q98178792 | Average daily gain divergence in beef steers is associated with altered plasma metabolome and whole blood immune-related gene expression |
| Q99609899 | Bisphenol A Exacerbates Allergic Inflammation in an Ovalbumin-Induced Mouse Model of Allergic Rhinitis |
| Q90599520 | Calcitriol Analogues Decrease Lung Metastasis but Impair Bone Metabolism in Aged Ovariectomized Mice Bearing 4T1 Mammary Gland Tumours |
| Q94600779 | Cancer exosome-derived miR-9 and miR-181a promote the development of early-stage MDSCs via interfering with SOCS3 and PIAS3 respectively in breast cancer |
| Q97884258 | Changes in expression of interferon-stimulated genes and ubiquitin activating enzyme E1-like in ovine thymus during early pregnancy |
| Q97543017 | Constitutive activation of the EGFR-STAT1 axis increases proliferation of meningioma tumor cells |
| Q90726854 | DNA methylomes and transcriptomes analysis reveal implication of host DNA methylation machinery in BmNPV proliferation in Bombyx mori |
| Q60912812 | Enriched Cd141+ DCs in the joint are transcriptionally distinct, activated, and contribute to joint pathogenesis |
| Q60306477 | Expression analysis of protein inhibitor of activated STAT (PIAS) genes in IFNβ-treated multiple sclerosis patients |
| Q55549910 | Frequency of CD4+ and CD8+ T cells in Iranian chronic rhinosinusitis patients. |
| Q90133178 | Frequent Klebsiella pneumoniae Urinary Tract Infections in a Patient Treated with Ruxolitinib |
| Q91966309 | Gene regulation analysis of the effects of evodiamine on tongue squamous cell carcinoma |
| Q90026795 | Genomic Function of Estrogen Receptor β in Endometriosis |
| Q90147435 | Interleukin-9 Deletion Relieves Vascular Dysfunction and Decreases Blood Pressure via the STAT3 Pathway in Angiotensin II-Treated Mice |
| Q97523147 | JAK inhibitors and infections risk: focus on herpes zoster |
| Q92134267 | Long-Term Use of Ruxolitinib in an AML Patient with Posttransplant Steroid Refractory GVHD |
| Q64084289 | Molecular Cloning and Expression Analysis of Three Suppressors of Cytokine Signaling Genes (, , ) in the Mealworm Beetle |
| Q89861316 | Molecular Signaling Pathways and Therapeutic Targets in Hepatocellular Carcinoma |
| Q102211000 | Moving targets in drug discovery |
| Q64084623 | NF-κB Signaling and IL-4 Signaling Regulate SATB1 Expression via Alternative Promoter Usage During Th2 Differentiation |
| Q91989455 | Nilotinib interferes with cell cycle, ABC transporters and JAK-STAT signaling pathway in CD34+/lin- cells of patients with chronic phase chronic myeloid leukemia after 12 months of treatment |
| Q99637343 | Novel β-Coronavirus (SARS-CoV-2): Current and Future Aspects of Pharmacological Treatments |
| Q52602372 | Progranulin ameliorates coxsackievirus-B3-induced viral myocarditis by downregulating Th1 and Th17 cells. |
| Q64929696 | Roles of circular RNAs in immune regulation and autoimmune diseases. |
| Q58794418 | STAT3 expression is a prognostic marker in upper urinary tract urothelial carcinoma |
| Q90540850 | Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution |
| Q96762613 | Targeting adenosinergic pathway and adenosine A2A receptor signaling for the treatment of COVID-19: A hypothesis |
| Q107739555 | The Many Faces of JAKs and STATs Within the COVID-19 Storm |
| Q97416174 | The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19 |
| Q98947637 | The potential similarities of COVID-19 and autoimmune disease pathogenesis and therapeutic options: new insights approach |
| Q94594689 | The powerful immune system against powerful COVID-19: A hypothesis |
| Q64113812 | Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment |
| Q89896995 | Tissue Profile of CDK4 and STAT3 as Possible Innovative Therapeutic Targets in Urinary Bladder Cancer |
| Q97423207 | miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma |
Search more.